BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. With the global EP market projected to reach $7.4B in 2022 with a 10.4% growth rate, BioSig has commenced a targeted commercial release of its PURE EP™ System, generating its first commercial sale in December 2020. The Company’s first product is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP™ System received FDA 510(k) clearance in August 2018. Physicians using BioSig’s PURE EP™ System have successfully completed over 410 patient cases to date. Systems are currently installed at multiple locations, including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center.

Data Source: 2018 MD&D Report

Key Growth Drivers

1) **Advanced Technology** — The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving **accuracy and efficiency of the EP studies and ablation procedures.**

2) **Market Opportunity** — 2018 MD&D Report states the global EP device market is expected to exceed more than US $7.4 billion by 2022 and is growing at a compound annual growth rate (CAGR) of 10.4%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at $25.11 billion in 2020 with projected annual growth of 10.27%.

3) **KOL Support** — Successful clinical use of the PURE EP™ System was led by two globally recognized leaders: Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute (TCAI) and Prof. John M. Miller of Indiana University. The Company achieved proof of concept validation through UCLA, and has performed twenty-one pre-clinical studies at Mayo Clinic, MN under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

Recent Highlights

- Achieved first commercial sale
- Announced installation of the PURE EP™ System at Deborah Heart and Lung Center
- Announced positive responses confirming PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis
- Announced installation of the PURE EP™ System at Massachusetts General Hospital and the University of Pennsylvania
- Successfully completed **300 patient cases** with its PURE EP™ System
- Announced closing of **$17.8** million BioSig Technologies common stock offering in 06/20
- Announced closing of **$10** million public offering of BSGM common stock in 02/20
- Commenced **patient cases at Mayo Clinic**, the **second institution** enrolling patients in the PURE EP™ System Clinical Trial
- Announced that the US Patent & Trademark Office allowed a **fifth utility patent** covering PURE EP™
- Announced **partnership with Reified** on development of artificial intelligence (AI) solutions

Market Snapshot

<table>
<thead>
<tr>
<th>NASDAQ: BSGM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Price</strong> (12/15/20)</td>
</tr>
<tr>
<td><strong>Average Volume</strong> (30 day)</td>
</tr>
<tr>
<td><strong>52-Wk. Range</strong></td>
</tr>
<tr>
<td><strong>Float</strong></td>
</tr>
<tr>
<td><strong>Shares Outstanding</strong></td>
</tr>
<tr>
<td><strong>Market Cap</strong></td>
</tr>
</tbody>
</table>

BioSig Technologies, Inc.
54 Wilton Road, 2nd Floor
Westport, CT 06880
[www.biosig.com](http://www.biosig.com)
[info@biosigtech.com](mailto:info@biosigtech.com)

Contact:
Kenneth L. Londoner, CEO
Phone: (203) 409-5444 x119
klondoner@biosigtech.com

Investor Relations
Andrew Ballou
Phone: (203) 409-5444, x133
aballou@biosigtech.com

NASDAQ: BSGM
Investment Catalysts

PURE EP™ System

Proprietary Hardware and Software with Advanced Signal Processing Capabilities:
- To Improve Signal Clarity Through Reduction of ‘Noise’ and Artifacts
- To Minimize Need for Repeat Procedures
- To Preserve Important Clinical Information
- To Shorten Procedure Times
- To Increase Confidence in Performing Complex Ablations
- Customizable user control interface for a better understanding of ECG and intracardiac signals

Projected Global EP Market—10.4%

Growth reaching $7.4B by 2024
- Global Ablation Procedure Growth: 8.4% growth rate, from 973,220 in 2017 to 1,455 projected million in 2022.
- Complex Ablation Procedures: 440,629 in 2017 to 830,390 in 2022; 13.5% projected growth rate

Collaborating with Leading EPs from:

Management and Past Experience

Kenneth L. Londoner, MBA, Founder, Chairman, Chief Executive Officer, Director
Endicott Management Partners; J & W Seligman & Co; Director: Allilqua

Steve Chaussy, CPA, Chief Financial Officer
Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe

Natasha Drapeau, Executive Vice President
IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland

Barry Keenan, Ph.D, MBA, PMP, VP, Engineering
Medtronic, Nexeon MedSystems, Alfred Mann Institute for Biomedical Engineering; Alfred Mann Foundation for Scientific Research

John Kowalski, VP, Sales
Biosense Webster (Johnson & Johnson)

Andrew Ballou, VP, Investor Relations
Janny Montgomery Scott LLC, RBC Capital Markets

Todd Wilshire, Senior VP, Corporate Development
Fidelity Investments, Morgan Stanley

Julie Stephenson, VP, Clinical Affairs
Medtronic, Boston Scientific, Guidant Corporation

Olivier Chaudoir, Jr. Director of Marketing
Biosense Webster, DePuy Synthes

Proven Team

BioSig is operated by a proven management team and a premier Board of Directors with high levels of inside equity ownership.

BioSig brought together leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions for its Advisory Board including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

Kenneth L. Londoner, Chairman & CEO, has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to a number of life science companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing $3.5 billion in mutual funds, pension funds, and international assets.

Steve Chaussy, CFO has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and served as CFO for a large private distribution and wholesaling company, where he gained international experience.

Investment Highlights

- $32 Million cash and no debt
- Achieved first revenues
- Member of the Russell 3000® Index
- Conducting First Clinical Trial with PURE EP™ System
- Significant Insider Ownership
- 10-year Strategic Collaboration with Mayo Clinic
- IP Strategy: Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox—31 allowed/issued design and utility patents
- FDA clearance achieved
- Proven Management Team and Board of Directors
- Global and Growing Addressable Market
- Operates Within Rapidly Emerging Field of Bioelectronic Medicine

Current Cardiac Arrhythmia Epidemic (1 in 18 or 14.4M Americans)

Two of the most prevalent, complex and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for approximately 300,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.

Directors

Donald E. Foley, Director - Former CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co.

David Weid IV, MBA, Director - Current Chairman & CEO; Weid & Co.; Former Vice Chairman: NASDAQ; Former Head of Corporate Finance & Equity Markets: Prudential Securities

Patrick J. Gallagher, MBA, Director - Mgr Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Circulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody

Jeffrey F. O’Donnell, Sr., Director - Former CEO, Director: Trice Medical; Current Chair: SpectraWave; Director: Advamed Accel; Founder: Embrella Cardiovascular (sold to Edwards Lifesciences); CEO: PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash; Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director: Cardiac Science, Endologix

Andrew Filler, Director - Current Partner & General Counsel: Sherpa Technology Group, Nanosys; IP Counsel: Previvo Genetics; Board: Aira Technologies, Former: Caliper Life Sciences (sold to Perkin Elmer), Weil, Gotshal & Manges

Samuel E. Navarro, Director - Managing Partner: Gravitas Healthcare, LLC; Former Managing Director and Global Head of Medical Technology Investment Banking: Cowen & Company

Martha Pease, Director - Current Partner and Director at BCG (Boston Consulting Group)

Anthony Zook, Director - Former Vice President & Executive Officer at AstraZeneca Plc

Analyst Coverage: Laidlaw & Co

Disclaimer: This Corporate Summary Sheet includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and Biased risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or review its forward-looking statements. Data Sources: 2018 MD&D report, Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2018, CDC Fact Sheet on Atrial Fibrillation, American Heart Association, Ventricular Tachycardia in Medscape, December 2017, ‘Healthcare Costs Drop Sharp after Successful Ablation’, Marine Busin, Medscape, May 4, 2016, and Bioelectronic Medicine 2019-2020. ©Zacks Research